next announcement and likely content, page-84

Hey PLasticd, In the case of ATL1103 it shows effective IGF reduction early in treatment... which offers the clinical end point for acromegaly. ATL1103 is already outperforming Somavert at these early stages making it a quality and easy tie-in for anyone. I suspect with the attention ANP are receiving the wider pharmaceutical industry has very much caught on to this and is beginning the buttering up process.

Acromegaly market it is a 1 billion dollar market and ATL1103 performing as it is suggests ANP are already more than a shoe in.

“Target market for ATL1103 is at least the 35-40% of acromegalics who are not controlled on somatostatins, in addition to those who would switch from Somavert® because of therapy limitations = potential market opportunity of up to $500 mill/annum in acromegaly indication.”

Really it is a walk in the park for ANP if it performs on humans as it does on NHP. NHP vs humans are comparable in the sense of these trials. Plus remember Antisense Gen2 liver target drugs are now proven now with safety being excellent and unquestioned so the therapy in this application is somewhat effective.

P1 single ascending dosing commenced on June-29 and multi dose finished on Oct-11 with IGF monitoring.... so they will have a fair idea on how it should pan out. PII is a 12 week study 10,15 and 20mg per day and placebo.
ODA for is different to FDA check out the clinical presentation it is good reading.

Also, i read your other post regarding the diabetic retinopathy market BOOM lol.... best we get ATL1103 making some money first and tie-in for acromegaly will provide cash and the free carry needed to concentrate on other aspects or possible uses for these drugs.



JMO, and Good Luck!